Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Needs assessment for the establishment of an Oral Therapy Unit].
Vazquez L, Coussirou J, Grenier J, Billemont B, Mege A, de Rauglaudre G, Stancu A, David C, Durand A, Decrozals F, Arnaud A. Vazquez L, et al. Among authors: coussirou j. Bull Cancer. 2023 Feb;110(2):184-192. doi: 10.1016/j.bulcan.2022.10.005. Epub 2022 Nov 18. Bull Cancer. 2023. PMID: 36411129 French.
Identification of factors associated with aggressive end-of-life antitumour treatment: retrospective study of 1282 patients with cancer.
Debourdeau P, Belkacémi M, Economos G, Assénat E, Hilgers W, Coussirou J, Kouidri Uzan S, Vasquez L, Debourdeau A, Daures JP, Salas S. Debourdeau P, et al. Among authors: coussirou j. BMJ Support Palliat Care. 2024 Dec 19;14(e3):e2580-e2587. doi: 10.1136/bmjspcare-2020-002635. BMJ Support Palliat Care. 2024. PMID: 33154087
Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.
Loret EP, Darque A, Jouve E, Loret EA, Nicolino-Brunet C, Morange S, Castanier E, Casanova J, Caloustian C, Bornet C, Coussirou J, Boussetta J, Couallier V, Blin O, Dussol B, Ravaux I. Loret EP, et al. Among authors: coussirou j. Retrovirology. 2016 May 9;13(1):35. doi: 10.1186/s12977-016-0264-y. Retrovirology. 2016. PMID: 27160192 Free PMC article. No abstract available.
Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.
Loret EP, Darque A, Jouve E, Loret EA, Nicolino-Brunet C, Morange S, Castanier E, Casanova J, Caloustian C, Bornet C, Coussirou J, Boussetta J, Couallier V, Blin O, Dussol B, Ravaux I. Loret EP, et al. Among authors: coussirou j. Retrovirology. 2016 Apr 1;13:21. doi: 10.1186/s12977-016-0251-3. Retrovirology. 2016. PMID: 27036656 Free PMC article. Clinical Trial.